Results 271 to 280 of about 177,994 (348)

Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Biomarker testing plays a critical role in precision oncology by guiding targeted therapy selection. In Australia, public reimbursement for somatic tumor biomarker tests has expanded over the past decade, yet national data on utilization patterns, equity of access, and public expenditure remain limited. We identified all cancer biomarker tests
Leping Kong, Christine Y. Lu
wiley   +1 more source

The Effects of <i>BRCA1</i> and <i>BRCA2</i> Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC. [PDF]

Cells
Živić K, Boljević I, Nedeljković M, Matović M, Janković R, Tanić M.   +5 more
europepmc   +1 more source

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4091-4099, May 2026.
ABSTRACT Aims Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug‐target Mendelian randomization (
Xingyu Shen, Shan Luo, Jie Zheng, Celine Sze Ling Chui, Ian Chi Kei Wong, Eric Yuk Fai Wan, Catherine Mary Schooling, Shiu Lun Au Yeung   +7 more
wiley   +1 more source

Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort study. [PDF]

BMC Med
Yang R, MacInnis RJ, Milne RL, Nguyen-Dumont T, Maxwell WF, Genkinger JM, Glendon G, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer (kConFab), Ross EA, Andrulis IL, Colonna SV, Daly M, John EM, Kurian AW, Terry MB, Hopper JL, Southey MC, Phillips KA, Li S.   +18 more
europepmc   +1 more source

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population

, 2015
Frédéric Ancot, Suzanna L. Arcand, Anne‐Marie Mes‐Masson, Diane Provencher, Patricia N. Tonin   +4 more
openalex   +2 more sources

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, Volume 88, Issue 6, Page 1115-1125, May 2026.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 5, May 2026.
ABSTRACT Aim Despite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.
Yoh Watanabe, Tsukasa Baba, Shu Soeda, Hideki Tokunaga, Wataru Yamagami, Hiroyuki Nomura, Yoichi Kobayashi, Kei Kawana, Kiyoshi Yoshino, Yoshihito Yokoyama, Hirotaka Nishi, Hiroaki Kobayashi, Yukiko Matsuzawa, Shunsuke Oyamada, Satoru Takahashi, Satoru Nagase   +15 more
wiley   +1 more source

Regulatory BC200 RNA promotes breast carcinogenesis by repressing BRCA1 gene expression. [PDF]

iScience
Berardi V, Muslimov IA, Sun D, Militello G, Premsrirut P, Tiedge H.   +5 more
europepmc   +1 more source

In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain ...
Carina Dumo, Faheem, Peter J. Choi, Nicholas J. Pederson, Yuge Liu, Mike Dragunow, Thomas I‐H. Park, Katharine L. Diehl, Jiney Jose   +8 more
wiley   +1 more source

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling. [PDF]

Fam Cancer
Gislinge JIP, Byrjalsen A, Naver KV, Clausen HV, Ravn P, Petersen KR, Wadt KAW.   +6 more
europepmc   +1 more source